CD19 t-haNK

Phase 1Biologic

CD19 t-haNK is one of 2 biologic programs targeting Non-Hodgkin Lymphoma Refractory/ Relapsed. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkin Lymphoma Refractory/ RelapsedActive, not recruiting

Non-Hodgkin Lymphoma Refractory/ RelapsedPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Non-Hodgkin Lymphoma Refractory/ Relapsed

#DrugCompanyPhaseTrials

BAFF CAR-T

LLuminary Therapeutics

Phase 2

1 2

CD19 t-haNK

IImmunityBio, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Non-Hodgkin Lymphoma Refractory/ Relapsed

NCT06334991

Q2 2028

Phase 2Recruiting

Lymphoma

NCT07125872

Q4 2028

Phase 2Not yet recruiting

Lymphoma

NCT07477366

Clinical

Trials by Indication[1]

Lymphoma2 trials

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT07477366·20 enrolled

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Recruiting·IImmunityBio, Inc.·Phase 2·NCT07125872·20 enrolled

Diffuse Large B-Cell Lymphoma1 trial

QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma

Withdrawn·IImmunityBio, Inc.·Phase 1·NCT04052061

B-ALL1 trial

A Phase 1 Open-label Study of CD19 t-hANK as a Single Agent in Participants With Selected CD19+ Relapsed B-cell Acute Lymphoblastic Leukemia

Terminated·IImmunityBio, Inc.·Phase 1·NCT07556757·4 enrolled

Non-Hodgkin Lymphoma Refractory/ Relapsed1 trial

Open-Label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With Rituximab in Participants With Selected CD19+ and CD20+ Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·IImmunityBio, Inc.·Phase 1·NCT06334991·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CD19 t-haNK. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19 t-haNK compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19 t-haNK. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IImmunityBio, Inc.

CD19 t-haNK

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Lymphoma2 trials

Diffuse Large B-Cell Lymphoma1 trial

B-ALL1 trial

Non-Hodgkin Lymphoma Refractory/ Relapsed1 trial

References

Drug Info

Quick Facts

Related News